This study is designed to evaluate the safety and pharmacokinetics of zanubrutinib in subjects with impaired liver function in comparison with healthy subjects
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
29
A single oral dose of 80 mg Zanubrutinib will be administered.
University of Miami
Miami, Florida, United States
Orlando Clinical Research Center
Orlando, Florida, United States
Plasma concentration of Zanubrutinib (BGB-3111) to evaluate protocol specified PK parameters
Plasma concentration of Zanubrutinib (BGB-3111) to evaluate Area Under the Plasma Concentration-Time Curve (AUC) of Zanubrutinib
Time frame: Days 1, 2 & 3
Plasma concentration of Zanubrutinib (BGB-3111) to evaluate protocol specified PK parameters
Plasma concentration of Zanubrutinib (BGB-3111) to evaluate Maximum Observed Plasma Concentration (Cmax) of Zanubrutinib
Time frame: Days 1, 2 & 3
Treatment-Emergent Adverse Events (AE)
Percentage of Participants with Treatment-Emergent Adverse Events (AE)
Time frame: up to Day 17
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.